STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Overview of Twist Bioscience Corp

Twist Bioscience Corp is a pioneering synthetic biology company that has redefined the process of DNA synthesis using a proprietary semiconductor-based manufacturing platform. The company leverages innovative technology to produce high-quality synthetic DNA rapidly and cost-effectively. This breakthrough approach, characterized by synthesizing DNA on silicon rather than traditional plastic wells, positions Twist Bioscience as a disruptive force in the biotechnological landscape, driving advances in applications from biomedical research to industrial biotechnology.

Proprietary Technology and Manufacturing Process

At the heart of Twist Bioscience's operations is a state-of-the-art synthetic DNA manufacturing process. By employing a 10,000-well silicon platform, the company sidesteps the limitations inherent in conventional methods. The integration of semiconductor technology not only minimizes production inefficiencies but also ensures high throughput, which is crucial for applications requiring rapid gene synthesis and customization. This technical ingenuity underpins the company's ability to deliver:

  • High-quality oligonucleotides
  • Custom genes and genetic pathways
  • Complex chassis and complete genomes

Business Model and Revenue Generation

Twist Bioscience's business model is built on the dual pillars of technology licensing and direct sales. The company generates revenue by offering its synthetic DNA products to a wide range of customers including academic research institutions, biotechnology firms, and industrial manufacturers. Its cost-effective, rapid production capabilities allow clients to accelerate their research and development efforts, thereby reducing time-to-market for various applications. This operational efficiency is not only beneficial to its clients but also reinforces the company’s reputation for reliability and scalability in the synthetic biology market.

Market Position and Competitive Landscape

Operating in a highly specialized niche, Twist Bioscience has carved a unique position in the competitive synthetic biology ecosystem. The company differentiates itself through its disruptive manufacturing process and its capacity to produce synthetic biology tools at scale. In a market where reliability, speed, and cost-efficiency are paramount, Twist Bioscience’s strategic focus on overcoming production inefficiencies positions it as a significant player. Its technology challenges traditional paradigms and compels competitors to reconsider conventional manufacturing methods, thereby affirming its role as an innovator rather than a mere participant in the industry.

Applications and Industry Impact

The technology developed by Twist Bioscience has far-reaching implications across numerous sectors. In the field of biomedical research and personalized medicine, its rapid DNA synthesis paves the way for new diagnostics, targeted therapies, and advanced research into genetic disorders. Beyond healthcare, the company’s synthetic biology tools enable innovations in sustainable chemical production and improved agricultural practices, broadening the scope of applications into:

  • Biopharmaceutical research: Accelerating drug discovery and genetic screening.
  • Industrial biotechnology: Optimizing production processes for chemicals and materials.
  • Environmental monitoring: Developing in vivo diagnostics and biodetection solutions.

This multi-sector applicability underscores the versatility and transformative potential of Twist Bioscience's platform. By industrializing the engineering of biology, the company not only enhances research capabilities but also contributes significantly to sectors that rely on synthetic DNA for innovation and efficiency.

Operational Excellence and Research Ecosystem

Central to the success of Twist Bioscience is its commitment to operational excellence and continuous innovation. The company collaborates with a diverse ecosystem of researchers, academic institutions, and industrial partners, fostering an environment where technological breakthroughs are routinely translated into practical solutions. This collaborative approach ensures that every advancement in its manufacturing process is both rigorously validated and immediately deployable across a spectrum of research and industrial applications.

Scientific and Technical Expertise

Twist Bioscience is driven by a deep reservoir of scientific and technical expertise. The company’s team, comprised of leading experts in synthetic biology, semiconductor physics, and bioengineering, is instrumental in refining its technology and pushing the boundaries of what is possible in DNA synthesis. This expertise not only strengthens the company’s competitive position but also instills confidence in its ability to deliver reliable, high-quality synthetic biology products that meet the evolving needs of modern research and industry.

Integration into the Broader Biotechnology Landscape

The innovations from Twist Bioscience resonate well within the broader biotechnology and life sciences arenas. Its approach to DNA synthesis using semiconductor-based technology is widely recognized for its potential to revolutionize how genetic materials are produced and utilized. This integration of advanced material science with biotechnology exemplifies the cross-disciplinary innovation that is becoming increasingly important. Researchers and industrial partners alike appreciate the capacity for simultaneous high throughput and high precision, enabling a smoother transition from conceptual breakthroughs to tangible products.

Commitment to Quality and Reliability

Quality control and reliability are fundamental to Twist Bioscience’s operations. The company’s advanced manufacturing process ensures consistency and precision in synthetic DNA production. By employing robust quality assurance protocols throughout its production cycle, Twist Bioscience provides products that research institutions and industry players can depend upon for critical applications. This unwavering focus on quality not only supports current operational needs but also cements the company’s reputation as a trustworthy provider of synthetic biology tools.

Position within the Competitive Landscape

While the synthetic biology sector is competitive, Twist Bioscience’s distinctive approach allows it to maintain a unique market niche. Its semiconductor-based platform, coupled with the extensive scale and precision of production, sets it apart from more traditionally operated competitors. The company’s strategy of addressing the inherent inefficiencies of standard DNA synthesis methods resonates with clients looking for innovative solutions. This unique value proposition has enabled Twist Bioscience to develop a strong foothold in its primary markets, particularly in regions known for high research and development activity.

Conclusion

In summary, Twist Bioscience Corp represents a significant advancement in synthetic biology. Through its disruptive semiconductor-based synthetic DNA platform, the company not only accelerates research and industrial processes but also redefines the standards of cost efficiency and production quality. Its integrated approach, encompassing innovative technology, rigorous quality control, a collaborative research ecosystem, and a clear focus on operational excellence, makes it a compelling case study in modern biotechnology innovations. The breadth of its applications and its ability to deliver high-quality synthetic DNA at scale underscore its impact on the biotechnology industry and its sustained position in the competitive landscape.

Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its Twist Express Genes service to include larger DNA preparations, offering rapid gene synthesis at all gene prep scales, enabling large scale experimentation for pharmaceutical, biotechnology, academic, and industrial chemical researchers. The service has received positive feedback from customers for its consistent and rapid turnaround time. The company leverages its silicon-based DNA synthesis platform to deliver Clonal Genes and Gene Fragments at scale and with rapid turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will issue its financial results for the fiscal 2024 first quarter on February 2, 2024. The company plans to hold a conference call and live audio webcast to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website. The conference call will be webcast live and the webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences earnings
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 50,000 restricted stock units and 70,000 shares to its chief financial officer, Adam Laponis, as an inducement material to his acceptance of employment with Twist. The RSUs vest quarterly over a 48-month period, with the first 25% vesting on the one-year anniversary of Mr. Laponis' employment. The shares subject to the executive compensation programs include RSUs and performance stock units that vest based on achievement against established metrics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (TWST) appoints Adam Laponis as chief financial officer. Mr. Laponis brings extensive experience from Eargo, Inc., Tesla, Inc., and Cardinal Health, with a track record of driving profitable growth and increasing revenue. His appointment is expected to drive value for stakeholders and contribute to the company's growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
management
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO and co-founder Emily M. Leproust, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8. The presentation will be webcast live and can be accessed through the company's investor relations section. A replay will be archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $245.1 million in Fiscal 2023, a 20% increase over 2022. Orders also grew to $264 million, up 17% from 2022. Fiscal 2024 revenue is expected to range between $285 million to $290 million. The company's CEO, Dr. Emily M. Leproust, expressed optimism for the future, focusing on profitability and growth for the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) Launches Twist Express Genes, a new gene synthesis service with a turnaround time of five to seven business days. The service is enabled by the state-of-the-art Wilsonville manufacturing facility, offering high-quality synthetic DNA using its silicon platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.96%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces participation in the 6th Annual Evercore ISI HealthCONx Conference. CEO Emily M. Leproust and CFO Jim Thorburn will engage in a fireside chat on November 28 at 7:30 a.m. Eastern Time in Miami, FL. The webcast will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
conferences
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces grant of 130,400 restricted stock units to 15 new hires. The RSUs vest over a 48-month period, in accordance with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will release its financial results for the fiscal 2023 fourth quarter and full year on November 17, 2023. The company will hold a conference call and live webcast at 8:00 a.m. Eastern Time to discuss the results and provide a business update. The press release and webcast will be accessible from the company's website. Telephone participants must register in advance to receive the dial-in number and PIN. Webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
conferences earnings

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $40.27 as of April 10, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.4B.

What is Twist Bioscience's core business?

Twist Bioscience focuses on synthetic biology by utilizing a proprietary semiconductor-based platform to synthesize high-quality DNA. Its core business involves manufacturing synthetic DNA for research, industrial biotechnology, and biomedical applications.

How does Twist Bioscience's technology differ from traditional methods?

The company synthesizes DNA on silicon rather than on conventional plastic plates, enabling cost-effective, rapid, and high-throughput production while overcoming common inefficiencies in traditional synthesis methods.

Which industries benefit from Twist Bioscience's products?

Industries ranging from biomedical research and personalized medicine to industrial biotechnology and sustainable chemical production benefit from their high-quality synthetic DNA products.

What are the primary products provided by Twist Bioscience?

Twist Bioscience produces a range of synthetic biology tools including oligonucleotides, genes, genetic pathways, chassis, and complete genomes, all synthesized using their advanced silicon-based platform.

How does the company's business model support its operations?

The company generates revenue through direct sales and technology licensing, offering high-quality synthetic DNA products that enhance research capabilities and industrial production efficiency.

What competitive advantages does Twist Bioscience hold in the synthetic biology market?

Their proprietary technology, which leverages semiconductor manufacturing techniques, allows them to produce DNA faster and more cost-effectively than traditional methods, positioning them uniquely in the competitive landscape.

Who are the primary customers of Twist Bioscience?

Twist Bioscience serves a diverse customer base including academic research institutions, biotechnology companies, and industrial manufacturers requiring reliable synthetic DNA production for various applications.

How does Twist Bioscience ensure the quality of its synthetic DNA products?

By integrating rigorous quality control protocols within its manufacturing process, the company ensures consistent and precise production, making its products dependable for critical research and industrial applications.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.40B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO